NCT05544149

TRT for ES-SCLC After First Line Treatment With Immune Checkpoint Inhibitors

An Open-label, Phase II Single Arm Trial of Thoracic Radiotherapy for?ES-SCLC After First Line Treatment With Immune Checkpoint Inhibitors

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 42 (estimated)
• Sponsor: Zhejiang Cancer Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To Evaluate the Safety and Efficacy of Thoracic Radiotherapy for?ES-SCLC After First Line Treatment with Immune Checkpoint Inhibitors.

Conditions

• SCLC,Extensive Stage

Interventions

Type	Name	Description
RADIATION	Thoracic radiotherapy	Thoracic radiotherapy for ES-SCLC after first line immunecheckpoint inhibitors

Timeline

• Start date: 2022-09-01
• Primary completion: 2024-08-30
• Completion: 2025-08-30
• First posted: 2022-09-16
• Last updated: 2022-09-16

Locations

1 site across 1 country: China